Switch theme
Sign up to access all valuation multiples
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
1987
563
LTM Revenue n/a
LTM EBITDA n/a
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gen Ilac has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Gen Ilac achieved revenue of $214M and an EBITDA of $21.2M.
Gen Ilac expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gen Ilac valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $143M | $214M | XXX | XXX | XXX |
| Gross Profit | $12.0M | $30.0M | XXX | XXX | XXX |
| Gross Margin | 8% | 14% | XXX | XXX | XXX |
| EBITDA | $33.7M | $21.2M | XXX | XXX | XXX |
| EBITDA Margin | 24% | 10% | XXX | XXX | XXX |
| Net Profit | $8.2M | $28.4M | XXX | XXX | XXX |
| Net Margin | 6% | 13% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Gen Ilac's stock price is TRY 128 (or $3).
Gen Ilac has current market cap of TRY 38.3B (or $1.0B), and EV of TRY 39.1B (or $1.0B).
See Gen Ilac trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.0B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Gen Ilac has market cap of $1.0B and EV of $1.0B.
Gen Ilac's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Gen Ilac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Gen Ilac and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | 48.4x | XXX | XXX | XXX |
| P/E | 84.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -73.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGen Ilac's NTM/LTM revenue growth is n/a
Gen Ilac's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Gen Ilac's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Gen Ilac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Gen Ilac and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 50% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -37% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 15% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gen Ilac acquired XXX companies to date.
Last acquisition by Gen Ilac was XXXXXXXX, XXXXX XXXXX XXXXXX . Gen Ilac acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Gen Ilac founded? | Gen Ilac was founded in 1987. |
| Where is Gen Ilac headquartered? | Gen Ilac is headquartered in Turkey. |
| How many employees does Gen Ilac have? | As of today, Gen Ilac has 563 employees. |
| Is Gen Ilac publicy listed? | Yes, Gen Ilac is a public company listed on IST. |
| What is the stock symbol of Gen Ilac? | Gen Ilac trades under GENIL ticker. |
| When did Gen Ilac go public? | Gen Ilac went public in 2021. |
| Who are competitors of Gen Ilac? | Similar companies to Gen Ilac include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Gen Ilac? | Gen Ilac's current market cap is $1.0B |
| What is the current revenue growth of Gen Ilac? | Gen Ilac revenue growth between 2023 and 2024 was 50%. |
| Is Gen Ilac profitable? | Yes, Gen Ilac is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
